Clinical trial
A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury
NCT02193334 is registered in ClinicalTrials.gov with Kringle Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury
- Lead sponsor
- Kringle Pharma, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 30, 2014
- Completion date
- July 31, 2018
- Enrollment
- 45 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.